Skip to main content
OpenTrials
Completed

NCT Number: NCT02175602

Study of Drug Combination on Pharmacokinetics in Healthy Volunteers

The purpose of this study is to assess the effect of Daclatasvir, Asunaprevir, and BMS-791325 on the pharmacokinetics of selective serotonin reuptake inhibitors.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed Informed Consent Form

a) Signed written informed consent must be obtained from the subjects in accordance with requirements of the study center's IRB or IEC before the initiation of any protocol-required procedures.

  • Target Population

a) Healthy subjects as determined by no clinically significant deviation from normal in medical history, psychiatric history, physical examination findings, vital sign measurements, 12-lead ECG measurements, physical measurements, and clinical laboratory test results.

  • Age and Reproductive Status
  • Males and females, ages 25 to 55 years, inclusive.
  • Women of childbearing potential (WOCBP) must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug.
  • Women must not be breastfeeding.

Exclusion criteria

  • Any significant acute or chronic medical illness.
  • Current or recent (within 3 months of study drug administration) gastrointestinal disease that could impact upon the absorption of study drug (appendectomies with no complications are allowed at the investigator's discretion).
  • Any major surgery within 4 weeks of study drug administration.
  • Smokers (those who currently smoke, as well as those who have stopped smoking less than 6 months prior to the start of study drug administration).
  • Any other sound medical, psychiatric, and/or social reason as determined by the investigator.

Treatment and study plan

Escitalopram

Drug

10 milligrams administered each morning

Other names: Lexapro

Sertraline

Drug

50 milligrams administered each morning

Other names: Zoloft

DCV 3DAA FDC

Drug

Fixed dose combination (daclatasvir [DCV] 30 milligrams, asunaprevir [ASV] 200 milligrams, and BMS-791325 75 milligrams) one tablet administered twice daily

BMS-791325

Drug

75 milligrams single-agent film coated oral tablet administered twice daily

Primary outcomes

  1. Serial blood samples for plasma SSRI (selective serotonin reuptake inhibitor) of escitalopram or sertraline

    Time frame: Before dosing (0 hour) through 24 hours after SSRI administration on day 7 and day 29

  2. Serial blood samples for determination of plasma concentrations of DCV (daclatasvir), ASV (asunaprevir), BMS-791325, and the metabolite BMS-794712

    Time frame: Before dosing (0 hour) through 12 hours after SSRI administration on day 22 and day 29

Secondary outcomes

  1. Safety assessments based on review of adverse events, vital sign measurements, electrocardiograms, physical examinations, and clinical laboratory tests.

    Time frame: Two to three months

Sponsors and collaborators

Lead sponsor

Bristol-Myers Squibb

Industry

Registry information

Official study title

Effect of a Combination of Daclatasvir, Asunaprevir, and BMS-791325 on the Pharmacokinetics of Selective Serotonin Reuptake Inhibitors in Healthy Subjects

Important dates

Study start
2014
Primary completion
2014
First posted
Jun 26, 2014
Registry last updated
Feb 10, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.